No Data
No Data
NeuroSense Therapeutics Shares Are Trading Higher. The Stock May Be Moving on a Continued Strength After the Company Reported on Wednesday a Year-over-year Increase in 9-month EPS Results.
NeuroSense Therapeutics: Expect to Submit a Dossier in 2Q 2025, With a Regulatory Decision Expected by 1Q 2026 >NRSN
NeuroSense Therapeutics: Estimate Potential Market Opportunity in Canada Is Between $100M to $150M in Peak Annual Rev >NRSN
NeuroSense Therapeutics: Initiated the Regulatory Process to Seek Early Commercialization Approval for PrimeC Under Health Canada >NRSN
NeuroSense Therapeutics: As of Sept 30, 2024, Had Cash of $340,000, Which Does Not Include Gross Proceeds of $5M From Financing Completed in Dec >NRSN
Express News | Neurosense Therapeutics 9M EPS USD -0.48